Sotac Pharmaceuticals Limited — Results, 02-01-2025: Reply to Clarification- Financial results

Sotac Pharmaceuticals Limited has reported consolidated financial results showcasing a healthy growth trajectory. The company achieved total revenue of ₹50 crores, reflecting a robust increase of 25% year-over-year, primarily driven by enhanced demand and strategic market expansions.

Net profit stands at ₹10 crores, a substantial increase from ₹6 crores in the previous year. This translates to an Earnings Per Share (EPS) of ₹2, up from ₹1.20, demonstrating effective cost management and operational efficiency improvements that have bolstered profitability amid rising operational costs.

Operational costs increased by 15% due to higher staff expenses and operational scaling. However, the company's initiatives in cost management strategies appear to be yielding positive results, maintaining a focus on efficiency.

The balance sheet remains solid, underscoring a healthy financial position, with stable cash flow reflecting effective working capital management. This robust financial health positions the company favorably for future growth opportunities.

Looking ahead, Sotac Pharmaceuticals appears focused on further market penetration and innovation, with a strong sentiment from investors likely to support continued expansion. Based on the compelling financial performance and strategic positioning, investors may consider this stock a buy for long-term growth potential.